Attovia Therapeutics KOL event & Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon and welcome to the Attovia Therapeutics virtual KOL call and ATTO-1310 clinical development update. At this time, all attendees are in a listen-only mode. A live Q&A session will follow the formal presentations. To our covering analysts, please use the raise hand feature to be added to the queue. As a reminder, this call is being recorded and a replay will be available on the company website after the event. I will now turn the call over to Tao Fu, founder and CEO of Attovia Therapeutics.
Please go ahead, Tao. Good afternoon, everyone, and thank you for joining us.
I am Tao Fu, founder and CEO of Attovia Therapeutics. We are hosting a virtual KOL call and clinical development update for ATTO-1310, our lead clinical asset and the next-generation precision itch therapy targeting IL-31. Today, we are sharing the top-line 12-week results for our phase I-B study in chronic pruritus and high-itch atopic dermatitis. Earlier this afternoon, we issued a press release with these results, which is available on the investor section of our website. I am pleased to be joined by two of the world's leading experts in itch and atopic dermatitis, Dr. Brian Kim and Dr. Jonathan Silverberg. Also with me are Hubert Chen, our Chief Medical Officer, who will present the data, Steve Chan, our CFO, and Petter Veiby, our Chief Scientific Officer, who will join us for Q&A. Steve, over to you. Thank you, Tao.
Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements, which are subject to risks and uncertainties. Please review the disclosures on this slide and in our SEC filings, including the disclosures regarding cross-trial comparisons.
Back to you, Tao. Here is our agenda for today.
I will start with a brief overview of ATTO-1310. Dr. Kim and Dr. Silverberg will then share their perspectives on the significant unmet need in chronic pruritus of unknown origin, or CPUO, and in high-itch atopic dermatitis. Hubert will walk through the top-line 12-week results of our phase I-B study, followed by our phase II plans. I will come back at the end to share what we believe these data mean for ATTO-1310, and then we will open it up for questions. Shifting to the focus of today's call, ATTO-1310, I would like to explain why we believe this molecule is differentiated. ATTO-1310 is a next-generation precision itch therapy. It is an anti-IL-31 antibody fused to a half-life extended Fc given subcutaneously. IL-31 is a key driver of itch. Nemolizumab, which targets the IL-31 receptor alpha, has validated the IL-31 pathway and has seen strong commercial uptake.
When we designed ATTO-1310, our goal was to create a next-generation IL-31 medicine with a differentiated product profile across several key attributes. First, rapid itch relief. We targeted IL-31 ligand itself rather than its receptor. Cytopoint, an anti-IL-31 ligand antibody used in dogs, can deliver itch relief within hours, and we believe ligand targeting can produce faster onset. Second, deep efficacy. The ATTOBODY platform gives us ultra-high affinity and potency, and by targeting the ligand, we believe we can avoid the reverse dose efficacy seen with nemolizumab in multiple phase II studies, where the highest dose performed worse than lower doses. Third, a benign and differentiated safety profile, including the potential for fewer dermatitis adverse events. Last but not least, quarterly maintenance dosing compared with nemolizumab, which is primarily a monthly drug. Before we hear from our experts, let me share how we think about our phase I-B study.
Our week four interim analysis, which we previously shared, gave us a clean signal and the confidence we needed to advance into phase II. In addition to a favorable safety and immunogenicity profile, we saw rapid deep itch reduction by week four after one single dose in two different pruritic conditions, one with skin lesions and one without. We identified active doses to take forward to phase II, which is already underway. Now, with the full 12-week follow-up data in hand, I am very pleased to say that these data reinforced our confidence that ATTO-1310 can deliver the compelling target product profile we set out to achieve that we believe is significantly differentiated from nemolizumab. First, target engagement and drug exposure support quarterly dosing. Second, clinical activity was durable, extending beyond week four through week 12 after just one dose.
Third, the favorable safety and immunogenicity profile remained consistent through the full follow-up. We also have preliminary clinical and biomarker data suggesting a potentially differentiated safety profile. With that, before Hubert Chen walks through the data, it is important to spend time on the diseases themselves and the patients we are trying to help. We are very fortunate to have two leading experts with us today to discuss this unmet need in CPUO and high-itch atopic dermatitis. Dr. Brian Kim is Vice President and Chief Biotechnology Officer at Northwell Health and Professor at the Feinstein Institutes for Medical Research. He was previously Professor and Vice Chairman of Research at Mount Sinai. Brian is one of the leading scientists in the field of neuroinflammation and itch, and he has helped design multiple pivotal trials in dermatology for agents like dupilumab. Brian will speak on CPUO.
Dr. Jonathan Silverberg is Professor of Dermatology at The George Washington University School of Medicine, where he is a Director of Clinical Research and Contact Dermatitis. He was lead investigator for the nemolizumab phase III ARCADIA program, and Jonathan will speak on high-itch atopic dermatitis. Thank you both for joining us today. Brian, over to you. Thank you, Tao.
I will be speaking about chronic pruritus of unknown origin, or CPUO. This is a disease that is very near and dear to my heart. It is a disease that I see most in my clinic, and we have gone through a very interesting journey where it went from, is it a disease, to now what I think you will be convinced after today that it very much is a disease. So it is chronic itch lasting for greater than or equal to six weeks, where there is no clearly defined cause. It is typically associated with aging. It is much more prevalent within the elderly, and it is a generalized itch in nature, but highly prevalent, affecting 2 million to 5 million patients and adults in the U.S. There are no FDA-approved treatments yet, and its disease burden is quite tremendous.
The itch is typically quite severe, long-lasting, continuously on a daily basis, and strongly associated with anxiety and depression. As you see here in the picture on the left, this is a patient of mine who you can tell he is itchy just by looking because you see scratch marks where he can reach, and not where he cannot. We have been working on this disease for a while. There is a relatively simple way in which you can actually get to the diagnosis, although it is a diagnosis of exclusion. You take a very simple medical history. There are physical exam findings that you can exclude to rule out dermatologic conditions and basic laboratory tests. This is a schematic that we published a number of years ago.
CPUO, although a diagnosis of exclusion, is one we can very consistently diagnose in the clinic, and in fact, this is what I do most of my time as a clinician and dermatologist. Where are we at now in 2026? We ourselves were able to instigate a phase III clinical trial with dupilumab, which blocks the IL-4 receptor alpha in CPUO. Here are results in the phase III study. Although it did not meet its primary endpoint based on the proportion of patients reaching itch reduction at 24 weeks, a 4-point reduction, if the primary endpoint were 12 weeks, it would have actually met the primary endpoint. This is study A. Just to frame this, at week 12, these patients have received now seven injections of dupilumab.
Also, nemolizumab, which blocks the IL-31 receptor, the pruritogen or itch cytokine, is now in phase II clinical trials as well, which I will speak to a little bit based on my own experience later as well. Nemolizumab is a very promising agent, of course. There is remibrutinib, another drug that we are quite familiar with. It is a BTK inhibitor that is now FDA approved for chronic spontaneous urticaria and inducible urticaria that is also going into CPUO in phase III clinical trials. Then what you are hearing about today is ATTO-1310, which targets not the receptor, but now IL-31 ligand with positive phase I-B data now. We believe now the pipeline is rich and promising and exciting for chronic pruritus of unknown origin, which is in stark contrast to over 10 years ago when we first were exploring this disease and indication.
Dupilumab in CPUO, we have anecdotally found in a case series fashion from our own clinic that patients with CPUO can respond. This was very important for us, even though this is simply a case series, not a randomized controlled trial, but this was really gathering evidence that we can actually pharmacologically intervene in this condition. This drove the conviction that, in fact, this is a tractable condition, and I think increasingly, we will see this more and more with a number of different therapeutics in this space. We also have great experience with nemolizumab in the clinic off-label for CPUO as well. There is also a potential problem with nemolizumab, which there were some hints of in the clinical trials for atopic dermatitis, where we saw aggravation of atopic dermatitis as a flare, as a side effect potentially in the clinical trials.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
